Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections

ClinicalTrials.gov ID: NCT03510351

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03510351. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Clinical Outcomes With Ceftolozane-tazobactam in Patients With Multi Drug Resistant (MDR) Pseudomonas Aeruginosa Infections

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will describe clinical outcomes in patients who received ceftolozane-tazobactam for a Pseudomonas aeruginosa infection. Primary outcomes include 30-day and in-hospital mortality.

Study identification

NCT ID: NCT03510351
Recruitment status: Completed
Study type: Observational
Phase: Not listed
Lead sponsor: Temple University; Other
Enrollment: 200 participants

Conditions and interventions

Conditions

Interventions

Ceftolozane-Tazobactam Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 1, 2017 (Actual)
Primary completion: Feb 28, 2018 (Actual)
Completion: Feb 28, 2018 (Actual)
Last update posted: May 22, 2026

2017 – 2018

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Temple University, School of Pharmacy	Philadelphia	Pennsylvania	19140	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03510351, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 22, 2026 · Synced Nov 12, 2026